Premium
Safety of magnetic resonance imaging contrast agents
Author(s) -
Shellock Frank G.,
Kanal Emanuel
Publication year - 1999
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/(sici)1522-2586(199909)10:3<477::aid-jmri33>3.0.co;2-e
Subject(s) - contrast (vision) , magnetic resonance imaging , medicine , adverse effect , radiology , intravenous contrast , medical physics , computed tomography , computer science , pharmacology , artificial intelligence
Many of the MR examinations performed in the world each year are accompanied by administration of one of these frequently used intravenous contrast agents: Magnevist, Omniscan, and ProHance. Accordingly, MR practitioners must understand the basic pharmacokinetics, side effects, and the potential for adverse events for these contrast agents. Additionally, MR practitioners must know how to manage side effects and adverse events that may occur in association with the administration of contrast agents. Notably, the use of MR imaging contrast agents in special patient populations must be understood. This article discusses each of these important issues. J. Magn. Reson. Imaging 1999;10:477–484. © 1999 Wiley‐Liss, Inc.